Cholinergic and Dopaminergic Alterations in Nigrostriatal Neurons Are Involved in Environmental Enrichment Motor Protection in a Mouse Model of Parkinson's Disease

Overview

Journal J Mol Neurosci

Specialties Molecular Biology
Neurology

Date 2016 Sep 24

PMID 27660217

Citations 9

Authors

Willyan Franco Hilario

Alice Laschuk Herlinger

Lorena Bianchine Areal

Livia Silveira de Moraes

Tamara Andrea Alarcon Ferreira

Tassiane Emanuelle Servane Andrade

Cristina Martins-Silva

Rita Gomes Wanderley Pires

Affiliations

Soon will be listed here.

Abstract

Parkinson's disease (PD) is the second most common neurodegenerative disease in the world, being characterized by dopaminergic neurodegeneration of substantia nigra pars compacta. PD pharmacotherapy has been based on dopamine replacement in the striatum with the dopaminergic precursor 3,4-dihydroxyphenylalanine (L-DOPA) and/or with dopaminergic agonists, alongside anticholinergic drugs in order to mitigate the motor abnormalities. However, these practices neither prevent nor stop the progression of the disease. Environmental enrichment (EE) has effectively prevented several neurodegenerative processes, mainly in preclinical trials. Several studies have demonstrated that EE induces biological changes, bearing on cognitive enhancement, neuroprotection, and on the attenuation of the effects of stress, anxiety, and depression. Herein, we investigated whether EE could prevent the motor, biochemical, and molecular abnormalities in a murine model of PD induced by 1-methyl-4-phenyl-2,3-dihydropyridine (MPTP). Our results show that EE does not prevent the dopaminergic striatal depletion induced by MPTP, despite having averted the MPTP-induced hyperlocomotion. However, it was able to slow down and avoid, respectively, the 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) depletion. Analysis of dopaminergic mRNA alterations in the midbrain showed that D1R expression was increased by MPTP, while the normal expression level of this receptor was restored by EE. As for the cholinergic system, MPTP led to a decrease in the ChAT gene expression while increasing the expression of both AChE and M1R. EE attenuated and prevented-respectively-ChAT and M1R gene expression alterations triggered by MPTP in the midbrain. Overall, our data brings new evidence supporting the neuroprotective potential of EE in PD, focusing on the interaction between dopaminergic and cholinergic systems.

Citing Articles

Diosgenin derivative ML5 attenuates MPTP-induced neuronal impairment via regulating AMPK/PGC-1α-mediated mitochondrial biogenesis and fusion/fission.

Fan J, Ding W, Liang Y, Wei Y, Huang Y, Ma L Am J Transl Res. 2024; 16(8):3582-3598.

PMID: 39262707 PMC: 11384354. DOI: 10.62347/JBRE5043.

Molecular mechanisms underlying the neuroprotection of environmental enrichment in Parkinson's disease.

Alarcon T, Presti-Silva S, Simoes A, Ribeiro F, Pires R Neural Regen Res. 2022; 18(7):1450-1456.

PMID: 36571341 PMC: 10075132. DOI: 10.4103/1673-5374.360264.

Environmental Enrichment Protects Against Sepsis-Associated Encephalopathy-Induced Learning and Memory Deficits by Enhancing the Synthesis and Release of Vasopressin in the Supraoptic Nucleus.

Jiang S, Wang Y, Tang Y, Lu X, Guo D J Inflamm Res. 2022; 15:363-379.

PMID: 35079222 PMC: 8776728. DOI: 10.2147/JIR.S345108.

Poly (I:C)-induced maternal immune activation modifies ventral hippocampal regulation of stress reactivity: prevention by environmental enrichment.

Zhao X, Mohammed R, Tran H, Erickson M, Kentner A Brain Behav Immun. 2021; 95:203-215.

PMID: 33766701 PMC: 8187276. DOI: 10.1016/j.bbi.2021.03.018.

From the Gut to the Brain and Back: Therapeutic Approaches for the Treatment of Network Dysfunction in Parkinson's Disease.

Paolone G Front Neurol. 2020; 11:557928.

PMID: 33117258 PMC: 7575743. DOI: 10.3389/fneur.2020.557928.

References

Ferguson S, Law C, Sarkar S . Chronic MPTP treatment produces hyperactivity in male mice which is not alleviated by concurrent trehalose treatment. Behav Brain Res. 2015; 292:68-78. DOI: 10.1016/j.bbr.2015.05.057. View

Brandon E, Mellott T, Pizzo D, Coufal N, DAmour K, Gobeske K . Choline transporter 1 maintains cholinergic function in choline acetyltransferase haploinsufficiency. J Neurosci. 2004; 24(24):5459-66. PMC: 6729318. DOI: 10.1523/JNEUROSCI.1106-04.2004. View

Brandon E, Lin W, DAmour K, Pizzo D, Dominguez B, Sugiura Y . Aberrant patterning of neuromuscular synapses in choline acetyltransferase-deficient mice. J Neurosci. 2003; 23(2):539-49. PMC: 6741871. View

Hagino Y, Kasai S, Fujita M, Setogawa S, Yamaura H, Yanagihara D . Involvement of cholinergic system in hyperactivity in dopamine-deficient mice. Neuropsychopharmacology. 2014; 40(5):1141-50. PMC: 4367456. DOI: 10.1038/npp.2014.295. View

Rajput A . Levodopa prolongs life expectancy and is non-toxic to substantia nigra. Parkinsonism Relat Disord. 2001; 8(2):95-100. DOI: 10.1016/s1353-8020(01)00023-2. View

Khakimova G, Kozina E, Buneeva O, Aksenova L, Medvedev A, Ugryumov M . Activity of Monoamine Oxidase in the Nigrostriatal System at Presymptomatic and Early Symptomatic Stages of Parkinsonism in Mice. Bull Exp Biol Med. 2015; 159(4):456-8. DOI: 10.1007/s10517-015-2990-x. View

Schapira A, Bezard E, Brotchie J, Calon F, Collingridge G, Ferger B . Novel pharmacological targets for the treatment of Parkinson's disease. Nat Rev Drug Discov. 2006; 5(10):845-54. DOI: 10.1038/nrd2087. View

Bagga P, Chugani A, Patel A . Neuroprotective effects of caffeine in MPTP model of Parkinson's disease: A (13)C NMR study. Neurochem Int. 2015; 92:25-34. DOI: 10.1016/j.neuint.2015.11.006. View

Moriguchi S, Yabuki Y, Fukunaga K . Reduced calcium/calmodulin-dependent protein kinase II activity in the hippocampus is associated with impaired cognitive function in MPTP-treated mice. J Neurochem. 2011; 120(4):541-51. DOI: 10.1111/j.1471-4159.2011.07608.x. View

10.

Buxbaum A, Haimovich G, Singer R . In the right place at the right time: visualizing and understanding mRNA localization. Nat Rev Mol Cell Biol. 2015; 16(2):95-109. PMC: 4484810. DOI: 10.1038/nrm3918. View

11.

Heikkila R, Hess A, Duvoisin R . Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice. Science. 1984; 224(4656):1451-3. DOI: 10.1126/science.6610213. View

12.

Lundblad M, Picconi B, Lindgren H, Cenci M . A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function. Neurobiol Dis. 2004; 16(1):110-23. DOI: 10.1016/j.nbd.2004.01.007. View

13.

Lee F, Liu F . Genetic factors involved in the pathogenesis of Parkinson's disease. Brain Res Rev. 2008; 58(2):354-64. DOI: 10.1016/j.brainresrev.2008.02.001. View

14.

Bermudez M, Schultz W . Timing in reward and decision processes. Philos Trans R Soc Lond B Biol Sci. 2014; 369(1637):20120468. PMC: 3895993. DOI: 10.1098/rstb.2012.0468. View

15.

Hornykiewicz O . The discovery of dopamine deficiency in the parkinsonian brain. J Neural Transm Suppl. 2006; (70):9-15. DOI: 10.1007/978-3-211-45295-0_3. View

16.

Ding S, Li L, Zhou F . Nigral dopamine loss induces a global upregulation of presynaptic dopamine D1 receptor facilitation of the striatonigral GABAergic output. J Neurophysiol. 2015; 113(6):1697-711. PMC: 4359993. DOI: 10.1152/jn.00752.2014. View

17.

Gerfen C, Miyachi S, Paletzki R, Brown P . D1 dopamine receptor supersensitivity in the dopamine-depleted striatum results from a switch in the regulation of ERK1/2/MAP kinase. J Neurosci. 2002; 22(12):5042-54. PMC: 6757735. View

18.

Chen J, Swope D . Pharmacotherapy for Parkinson's disease. Pharmacotherapy. 2007; 27(12 Pt 2):161S-173S. DOI: 10.1592/phco.27.12part2.161S. View

19.

Solinas M, Thiriet N, Chauvet C, Jaber M . Prevention and treatment of drug addiction by environmental enrichment. Prog Neurobiol. 2010; 92(4):572-92. DOI: 10.1016/j.pneurobio.2010.08.002. View

20.

Benbir G, Ozekmekci S, Apaydin H, Delil S, Erginoz E . A hospital-based study: risk factors in development of motor complications in 555 Parkinson's patients on levodopa therapy. Clin Neurol Neurosurg. 2006; 108(8):726-32. DOI: 10.1016/j.clineuro.2006.02.002. View